Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Amniotic Allograft · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| Amniotic Suspension Allograft | BIOLOGICAL | This investigational product is a cryopreserved product derived from human amnion and cells from the amniotic fluid. |
| Placebo | DRUG | Matching placebo is 0.9% normal saline: 4 mL to be injected IA. |
Amniotic Allograft is an investigational therapy being developed for knee osteoarthritis. It is a form of amniotic suspension allograft, derived from amniotic tissue, and is currently in Phase 3 clinical development. The product is intended to address the symptoms of osteoarthritis in the knee, though it is not yet approved by regulatory authorities.
Amniotic Allograft is developed by Organogenesis Holdings Inc., a biopharmaceutical company traded on the stock exchange under the ticker ORGO. The company is conducting clinical trials to evaluate the efficacy of this amniotic suspension allograft for the treatment of knee osteoarthritis.
Amniotic Allograft is in Phase 3 clinical development for knee osteoarthritis. It is an investigational product, meaning it has not yet received regulatory approval and is still being studied in clinical trials to assess its safety and efficacy in patients.
Amniotic Allograft has been studied in two completed Phase 3 clinical trials for knee osteoarthritis. These trials are registered under NCT04636229, which enrolled 516 participants, and NCT06000410, which enrolled 594 participants. Both trials evaluated the efficacy of amniotic suspension allograft in patients with osteoarthritis of the knee.
Yes, Amniotic Allograft is also referred to as amniotic suspension allograft. The clinical trials for this product use the term amniotic suspension allograft to describe the investigational therapy being evaluated for knee osteoarthritis. This terminology reflects the composition of the product, which is derived from amniotic tissue.